Greenoaks and Sequoia led the round. The company reports positive preclinical results, but taking its first therapeutic programs into clinical trials remains a goal.
Isomorphic Labs plans to use its new capital to scale its IsoDDE drug-design engine, broaden its medicine pipeline and move its first therapeutic programs toward clinical trials. The November 17 Series C brings its May and November 2026 fundraising to $7.1 billion, but the company has not disclosed a new valuation. Its oncology and immunology programs have shown positive preclinical results; those findings are not yet evidence of results in people.
01
Greenoaks and Sequoia Capital co-led the $5 billion round; Andreessen Horowitz also joined as a new investor.
02
Alphabet continued to invest significantly, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund participated.
03
IsoDDE uses multiple simulation AI models to explore chemistry and help design drugs, building on work such as DeepMind’s AlphaFold.
Isomorphic Labs has secured $5 billion in fresh funding to develop AI-designed medicines as it works toward taking its first therapeutic programs into clinical trials. The November 17, 2026, Series C, co-led by Greenoaks and Sequoia Capital, follows another multibillion-dollar financing just six months earlier.
From a DeepMind spinout to a second major round
Founded by Demis Hassabis, Isomorphic spun out of DeepMind in 2021. Hassabis has led the company as CEO since then, pursuing a business focused on using AI to design and develop medicines.
Its previous financing was a $2.1 billion Series B in May 2026. The new round is more than twice that size, bringing the combined amount raised across those two rounds to $7.1 billion.
Andreessen Horowitz joined the Series C alongside several other new investors. Alphabet continued to invest significantly, according to Isomorphic’s announcement. All existing investors also participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Isomorphic did not disclose a new valuation, TechCrunch reported. The $5 billion represents money raised, rather than an announced value for the business.
Two financing rounds in 2026
$2.1 billion Series B
Isomorphic’s preceding financing took place in May.
$5 billion Series C
Greenoaks and Sequoia Capital co-led the new round.
From protein structures to potential medicines
The company’s work builds on DeepMind’s AlphaFold, an AI system that predicts a protein’s three-dimensional structure from its genetic sequence. Isomorphic’s own drug-design engine, called IsoDDE, uses multiple simulation AI models to explore different areas of chemistry and help design drugs.
Isomorphic says the funding will help scale that engine and its pipeline of potential treatments, while expanding into more types of medicine. The company has already struck deals with Eli Lilly, Novartis and Johnson & Johnson.
Isomorphic says its program has produced positive preclinical results in oncology and immunology. Those findings concern progress before clinical trials, rather than results from trials in people.
Hassabis said the round would accelerate work on foundational biology models and deepen the company’s understanding of disease. The objective, he said, is “driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
Sources
isomorphiclabs.comIsomorphic Labs announces Series C investment round - Isomorphic Labs
cnbc.comDemis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO
techcrunch.comIsomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch
Reader comments
Newest comments first. Replies stay oldest first.